Page last updated: 2024-11-05

dydrogesterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9051
CHEMBL ID1200853
CHEBI ID31527
SCHEMBL ID37703
MeSH IDM0006900

Synonyms (133)

Synonym
MLS002153947 ,
smr001233286
BRD-K68620903-001-03-1
gtpl2878
(9beta,10alpha)-pregna-4,6-diene-3,20-dione
NCGC00016413-01
NCGC00179445-01
6 dehydro 9 beta 10 alpha progesterone
6-dehydro-9.beta.,10.alpha.-progesterone
nsc-92336
diphaston
.delta.6-retroprogesterone
terolut
duphaston
gynorest
9-.beta.,6-diene-3,20-dione
9.beta.,6-diene-3,20-dione
pregna-4,20-dione, (9.beta.,10.alpha.)-
prodel
dufaston
6-dehydroretroprogesterone
retro-6-dehydroprogesterone
retroprogesterone, 6-dehydro-
duvaron
retrone
BPBIO1_000839
PRESTWICK3_000671
dehydrogesterone
dydrogesterona [inn-spanish]
pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)-
9-beta,10-alpha-pregna-4,6-diene-3,20-dione
dydrogesteronum [inn-latin]
9-beta,10alpha-pregna-4,6-diene-3,20-dione
6-dehydro-9 beta-10 alpha-progesterone
6-dehydro-9beta,10alpha-progesterone
didrogesterone [dcit]
hsdb 3321
nsc 92336
ccris 9069
einecs 205-806-8
(9-beta,10-alpha)-pregna-4,6-diene-3,20-dione
pregna-4,6-diene-3,20-dione, (9beta,10alpha)-
dydrogesteronum
CHEBI:31527 ,
didrogesterona
AB00513884
dydrogesterone ,
nsc92336
isopregnenone
hydrogesterone
152-62-5
gestatron
delta(sup 6)-retroprogesterone
10alpha-isopregnenone
didrogesterone
DB00378
hydrogestrone
6-dehydro-retro-progesterone
9beta,10alpha-pregna-4,6-diene-3,20-dione
delta(6)-retroprogesterone
gynorest (tn)
D01217
duphaston (tn)
dydrogesterone (jp17/usp/inn)
PRESTWICK2_000671
SPBIO_002682
PRESTWICK0_000671
PRESTWICK1_000671
BSPBIO_000761
(8s,9r,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
CHEMBL1200853
HMS1570G03
HMS2097G03
unii-90i02kle8k
90i02kle8k ,
dydrogesterone [usan:usp:inn:ban:jan]
dydrogesterona
dtxsid1022974 ,
dtxcid702974
tox21_110429
cas-152-62-5
HMS2230C10
S4097
AKOS015895532
dydrogesterone [hsdb]
dydrogesterone [usan]
pregna-4,6-diene-3,20-dione, (9.beta.,10.alpha.)
dydrogesterone [usp monograph]
dydrogesterone [orange book]
dydrogesterone [ep monograph]
dydrogesterone [who-dd]
dydrogesterone [inn]
dydrogesterone [mart.]
dydrogesterone [jan]
dydrogesterone [mi]
dydrogesterone [usp-rs]
JGMOKGBVKVMRFX-HQZYFCCVSA-N
CCG-220671
HY-B0257A
SCHEMBL37703
tox21_110429_1
NCGC00179445-03
W-108050
(9?,10?)-pregna-4,6-diene-3,20-dione
AB00513884_04
(1r,2s,10s,11s,14s,15s)-14-acetyl-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-6,8-dien-5-one
GS-6735
10alpha-pregna-4,6-diene-3,20-dione
SR-01000841256-2
sr-01000841256
dydrogesterone; 9beta,10alpha-pregna-4,6-diene-3,20-dione
HMS3714G03
NCGC00179445-04
pregna-4,6-diene-3,20-dione, (9b,10a)-
(8s,9r,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-8,9,10,11,12,13,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
Q4161380
BCP12878
AMY23414
BRD-K68620903-001-11-4
H10151
EN300-19767791
(1s,3as,3bs,9as,9br,11as)-1-acetyl-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one
dydrogesterona (inn-spanish)
dehydro-retroprogesterone
pregna-4,6-diene-3,20-dione, (9beta,10alpha)
dydrogesteronum (inn-latin)
dydrogesterone (usan:usp:inn:ban:jan)
dydrogesterone (usp-rs)
dibrogesterone
g03db01
dydrogesterone (ep monograph)
dydrogesterone (mart.)
dydrogesterone (usp monograph)

Research Excerpts

Overview

Dydrogesterone (DDG) is a synthetic progestin used in contraception and hormone replacement therapy. The drug is an effective and safe drug that is under-utilized due to limited clinical research.

ExcerptReferenceRelevance
"Dydrogesterone seems to be a safe treatment, but its long-term innocuity needs to be further proven."( [Dydrogesterone versus micronized vaginal progesterone as luteal phase support after fresh embryo transfer in IVF].
Bry-Gauillard, H; Dessapt, AL; Massin, N; Pasquier, M; Pietin-Vialle, C; Tataru, C, 2022
)
2.35
"Dydrogesterone is a representative drug used for luteal phase support, the efficacy of which has been clinically confirmed."( Evaluation of allylestrenol for clinical pregnancies in patients treated with assisted reproductive techniques: a retrospective, propensity score matched, observational study.
Ding, W; Sun, K; Xiu, Y; Xu, X; Yu, T; Yu, Y; Zhang, Q; Zhao, M, 2023
)
1.63
"Dydrogesterone (DDG) is a synthetic progestin used in contraception and hormone replacement therapy. "( Dydrogesterone affects the transcription of genes in visual cycle and circadian rhythm network in the eye of zebrafish.
Chen, HX; Huang, GY; Huang, MZ; Jiang, YX; Ma, DD; Shi, WJ; Xie, L; Ying, GG, 2019
)
3.4
"Dydrogesterone (DYG) is an alternative progestin in progestin-primed ovarian stimulation (PPOS) protocol with weaker pituitary suppression than medroxyprogesterone acetate (MPA) in normal ovulatory women. "( Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study.
Cai, R; Gao, H; Huang, J; Kuang, Y; Lin, J; Lu, X; Xie, Q; Zhu, J, 2019
)
2.22
"Dydrogesterone is an effective and safe drug that is under-utilized due to limited clinical research."( Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis.
Huang, Y; Peng, C; Zhou, Y, 2021
)
2.79
"Dydrogesterone is an orally active synthetic progestogen, with a molecular structure similar to that of natural progesterone. "( Dydrogesterone indications beyond menopausal hormone therapy: an evidence review and woman's journey.
Stute, P, 2021
)
3.51
"Dydrogesterone is a reasonable option and the choice of either of the medications should be based on cost and side effects."( Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis.
Amaral, AS; Barbosa, ACP; Barbosa, MWP; Iglesias, JR; Martins, WP; Nakagawa, HM; Nastri, CO; Valadares, NPB, 2018
)
1.72
"Dydrogesterone is a retro-progesterone preparation widely used for over a half century. "( The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: An open-label multicenter clinical study.
Azuma, Y; Endo, Y; Harada, T; Iba, Y; Kurioka, H; Noma, H; Ohata, Y; Ota, I; Sunada, H; Tagashira, Y; Taniguchi, F; Toda, T, 2019
)
2.25
"Dydrogesterone (DDG) is a synthetic progestin broadly used in human and veterinary medicine and has been widely detected in aquatic environments. "( Dydrogesterone affects the transcription of genes in GnRH and steroidogenesis pathways and increases the frequency of atretic follicles in zebrafish (Danio rerio).
Hu, LX; Huang, GY; Liu, YS; Shi, WJ; Xie, L; Ying, GG; Zhang, JN, 2019
)
3.4
"Dydrogesterone (DDG) is a synthetic progestin widely used in numerous gynecological diseases. "( Dydrogesterone exposure induces zebrafish ovulation but leads to oocytes over-ripening: An integrated histological and metabolomics study.
Jiang, YX; Ma, DD; Ong, CN; Shi, WJ; Ying, GG; Zhang, H; Zhang, JN, 2019
)
3.4
"Dydrogesterone is an oral retroprogesterone widely used to treat progesterone deficiencies, including irregular menstrual cycles (MCs). "( Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study.
Doshchanova, A; Eshimbetova, G; Pexman-Fieth, C; Podzolkova, N; Tatarchuk, T, 2016
)
3.32
"Oral dydrogesterone seems to be a promising drug for luteal support in woman undergoing IVF."( Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study.
Chakravarty, B; Chakravorty, N; Chaudhury, K; Ganesh, A; Goswami, S; Mukherjee, R, 2011
)
0.88
"Dydrogesterone (DG) is a widely used progestin, but its endothelial actions have not been thoroughly assessed."( Dydrogesterone exerts endothelial anti-inflammatory actions decreasing expression of leukocyte adhesion molecules.
Fu, XD; Garibaldi, S; Genazzani, AD; Genazzani, AR; Gopal, S; Mannella, P; Palla, G; Polak, K; Simoncini, T; Spina, S, 2012
)
2.54
"Dydrogesterone is a potent orally active progestogen that has been used in clinical practice for over 40 years. "( Use of dydrogesterone as a progestogen for oral contraception.
Boerrigter, PJ; Coelingh Bennink, HJ, 2003
)
2.22

Effects

Dydrogesterone (DD) has a chemical structure very close to that of natural progesterone, without androgenic effects. It has enhanced oral availability compared with progesterones.

Dydrogesterone (DD) has a chemical structure very close to that of natural progesterone, without androgenic effects. Oral dydrogeterone has been used for luteal phase support on an empirical basis since the early days of in vitro fertilization (IVF) treatment.

ExcerptReferenceRelevance
"Dydrogesterone has a molecular structure closely related to that of natural progesterone, but it has enhanced oral availability compared with progesterone. "( Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium.
Schindler, AE, 2009
)
2.1
"Dydrogesterone (DD) has a chemical structure very close to that of natural progesterone, without androgenic effects."( Bone effects of dydrogesterone in ovariectomized rats: a biologic, histomorphometric, and densitometric study.
Chappard, C; De Vernejoul, MC; Dougados, M; Kolta, S; Morieux, C; Roux, C, 1996
)
1.36
"Dydrogesterone (DYG) has been demonstrated to be an alternative progestin in the progestin-primed ovarian stimulation (PPOS) protocol with comparable oocyte retrieval and pregnancy outcomes. "( Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study.
Cai, R; Gao, H; Huang, J; Kuang, Y; Lin, J; Lu, X; Wang, N; Xie, Q, 2019
)
2.19
"Oral dydrogesterone has been used for luteal phase support on an empirical basis since the early days of in vitro fertilization (IVF) treatment. "( Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard?
Blockeel, C; Griesinger, G; Tournaye, H, 2018
)
1.51
"Dydrogesterone has a molecular structure closely related to that of natural progesterone, but it has enhanced oral availability compared with progesterone. "( Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium.
Schindler, AE, 2009
)
2.1
"Dydrogesterone also has largely neutral effects on hemostasis."( Effects of dydrogesterone on the vascular system.
Mueck, AO; Seeger, H, 2007
)
1.45
"Dydrogesterone (DD) has a chemical structure very close to that of natural progesterone, without androgenic effects."( Bone effects of dydrogesterone in ovariectomized rats: a biologic, histomorphometric, and densitometric study.
Chappard, C; De Vernejoul, MC; Dougados, M; Kolta, S; Morieux, C; Roux, C, 1996
)
1.36

Actions

Dydrogesterone does not inhibit ovulation at standard doses, is devoid of estrogenic or androgenic properties, and does not induce metabolic side effects. It is suitable for use throughout a woman's lifetime, from adolescence to older age.

ExcerptReferenceRelevance
"Dydrogesterone may cause significant, albeit delayed, liver dysfunction in pregnancy necessitating the need for liver transplantation."( Delayed Fulminant Hepatic Failure from Dydrogesterone-Related In Vitro Fertilization Therapy Requiring Liver Transplantation During Pregnancy.
Garas, G; Khor, TS; MacQuillan, GC; Malherbe, JAJ, 2020
)
1.55
"As dydrogesterone does not inhibit ovulation at standard doses, is devoid of estrogenic or androgenic properties, and does not induce metabolic side effects, it is suitable for use throughout a woman's lifetime, from adolescence to older age, for conditions associated with altered levels of endogenous progesterone."( Dydrogesterone indications beyond menopausal hormone therapy: an evidence review and woman's journey.
Stute, P, 2021
)
2.58
"Dydrogesterone appears to cause little, if any, lipid and lipoprotein changes and assessment in a larger population of postmenopausal women is warranted."( Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone.
Jesinger, DK; Lewis, B; Prescott, P; Siddle, NC; Turner, P; Whitehead, MI, 1990
)
1.22

Treatment

Dydrogesterone treatment of women at risk of pre-term delivery results in increased PIBF production and IL-10 concentrations. Treatment was only accompanied by the decrease in the uterine artery systolic/diastolic ratio.

ExcerptReferenceRelevance
"Dydrogesterone treatment of women at risk of pre-term delivery results in increased PIBF production and IL-10 concentrations, and lower concentrations of IFNγ and could be effective for prevention or treatment of pre-term labor."( Dydrogesterone and pre-term birth.
Hudic, I; Schindler, AE; Stray-Pedersen, B; Szekeres-Bartho, J, 2016
)
2.6
"Dydrogesterone treatment was only accompanied by the decrease in the uterine artery systolic/diastolic ratio."( Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone.
Bros, M; Czajkowska, A; Czajkowski, K; Mogilinski, M; Sienko, J; Szczecina, R, 2007
)
1.26
"Treatment with dydrogesterone or calcium plus vitamin D decreased symptom severity in a similar way (by 4.64% and 4.20%, respectively) and placebo was associated with a 3.42% decrease."( Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome.
Abdali, K; Khajehei, M; Parsanezhad, ME; Tabatabaee, HR, 2009
)
1.01
"Treatment with dydrogesterone or calcium plus vitamin D had a similar effect on symptom severity in women with PMS."( Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome.
Abdali, K; Khajehei, M; Parsanezhad, ME; Tabatabaee, HR, 2009
)
1.01
"The treatment with dydrogesterone was tolerated well in general, blood pressure and body weight were not altered significantly."( [Treatment of the premenstrual syndrome with a retroprogesterone (Duphaston)].
Strecker, JR, 1980
)
0.58
"Treatment with dydrogesterone did not alter the natural history of endometriosis or PRs when compared with placebo. "( A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis.
Barlow, DH; Collins, SA; Johal, B; Lindsay, PC; Overton, CE; Shaw, RW; Siddle, NC, 1994
)
0.88

Toxicity

ExcerptReferenceRelevance
" Therefore, it is a safe and effective treatment."( [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
Chen, H; Han, Y; Hu, WG; Hua, KQ; Li, XL; Long, QQ; Zhang, SF, 2010
)
0.58
" One serious adverse event (appendicitis) and three non-serious adverse events were reported."( Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: a post-marketing study.
Chauhan, N; Trivedi, N; Vaidya, V, 2016
)
0.73
" Further studies are needed to confirm if monitoring of M-III could minimalize adverse effects such as nephrotoxicity or infections."( Tacrolimus Metabolite M-III May Have Nephrotoxic and Myelotoxic Effects and Increase the Incidence of Infections in Kidney Transplant Recipients.
Borowiec, A; Chmura, A; Dadlez, M; Hryniewiecka, E; Jazwiec, R; Nazarewski, S; Paczek, L; Samborowska, E; Tszyrsznic, W; Zegarska, J; Zochowska, D, 2016
)
0.43
" Incidence of adverse drug reactions was 31."( The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: An open-label multicenter clinical study.
Azuma, Y; Endo, Y; Harada, T; Iba, Y; Kurioka, H; Noma, H; Ohata, Y; Ota, I; Sunada, H; Tagashira, Y; Taniguchi, F; Toda, T, 2019
)
0.81
" Results were reported in the context of overall adverse events (AEs) and segregated according to various progesterone-deficient conditions."( Dydrogesterone after 60 years: a glance at the safety profile.
Aguilera, A; Egarter, C; Ott, J, 2022
)
2.16

Compound-Compound Interactions

We compared efficacy of vaginal progesterone gel combined with oral dydrogesterone for HRT-FET lutein support. A 1-year, multicentre, double-blind, randomised study was conducted in 214 healthy postmenopausal women. We performed experiments in vitro with various hormone therapy preparations.

ExcerptReferenceRelevance
"Lipid and bone metabolism was studied in 165 healthy postmenopausal women treated with 2 mg 17 beta-estradiol continuously combined with one of four doses (2."( Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism.
Kenemans, P; Netelenbos, JC; Peters-Muller, ER; van de Weijer, PH; Voetberg, GA, 1994
)
0.51
" In a randomized, double blind study, we examined the effects of 6-month treatment with daily 17 beta-estradiol (E2; 2 mg, orally) continuously combined with one of four dosages [2."( Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women.
Kenemans, P; Mijatovic, V; Netelenbos, JC; Peters-Muller, ER; van de Weijer, PH; van der Mooren, MJ; van Kamp, GJ; Voetberg, GA, 1997
)
0.55
"To investigate the effects of oral 17beta-estradiol administration continuously combined with dydrogesterone on fasting serum total homocysteine levels in postmenopausal women."( Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.
Jakobs, C; Kenemans, P; Mijatovic, V; Netelenbos, C; Peters-Muller, ER; Popp-Snijders, C; van der Mooren, MJ, 1998
)
0.76
"Oral micronized 17beta-estradiol (2 mg/d) continuously combined with one of four dosages of dydrogesterone (2."( Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.
Jakobs, C; Kenemans, P; Mijatovic, V; Netelenbos, C; Peters-Muller, ER; Popp-Snijders, C; van der Mooren, MJ, 1998
)
0.76
" A 1-year, multicentre, double-blind, randomised study was conducted in 214 healthy postmenopausal women in order to assess the effect of 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) in preventing bone loss."( 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women.
Lees, B; Stevenson, JC; Teter, P, 2001
)
0.75
"The bleeding pattern associated with low-dose (1 mg) estradiol sequentially combined with 5 or 10 mg dydrogesterone shows a high rate of amenorrhea in each cycle; there is a dydrogesterone dose effect on the occurrence and day of onset of bleeding."( Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone.
Barentsen, R; Kenemans, P; Scholten, PC; van de Weijer, PH; van der Mooren, MJ, 1999
)
0.73
"To assess the endometrial safety and bleeding patterns of 17 beta-estradiol sequentially combined with dydrogesterone."( Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone.
Ferenczy, A; Gelfand, MM; Rioux, JE; van de Weijer, PH, 2002
)
0.74
"Endometrial safety and bleeding patterns were assessed in 579 postmenopausal women randomized to oral treatment with placebo, 1 mg/day 17 beta-estradiol sequentially combined with 5 or 10 mg/day dydrogesterone for the last 14 days of each 28-day cycle, or 2 mg/day 17 beta-estradiol sequentially combined with 10 or 20 mg/day dydrogesterone for the last 14 days of each 28-day cycle."( Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone.
Ferenczy, A; Gelfand, MM; Rioux, JE; van de Weijer, PH, 2002
)
0.71
"This double-blind, placebo-controlled study involved 579 postmenopausal women randomized to oral treatment with placebo, 1 mg/day 17beta-estradiol sequentially combined with 5 or 10 mg/day dydrogesterone for the last 14 days of each 28-day cycle, or 2 mg/day 17beta-estradiol sequentially combined with 10 or 20 mg/day dydrogesterone for the last 14 days of each 28-day cycle."( 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women.
Gelfand, M; Komer, L; Rioux, JE; Stevenson, JC, 2005
)
0.77
"To compare the effect on total cholesterol and LDL and HDL cholesterol of oral dydrogesterone and medroxyprogesterone administration combined with continuous transdermal supplementation of 17beta-estradiol in postmenopausal women."( [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
Kostecka, A; Krzysiek, J; Kwiatkowska-Panek, E; Milewicz, T; Radowick, S; Rogatko, I; Sztefko, K, 2007
)
0.77
" The objective of this study was to analyze the effect of fulvestrant alone or in combination with different steroids in human breast cancer cells in vitro, and to demonstrate whether these steroids will compromise the efficacy of fulvestrant in ER-positive breast cancer cells."( Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Brinkhuis, M; Franke, HR; Jansen, GH; Vermes, I; Wolbers, F, 2008
)
0.35
"We performed experiments in vitro with various hormone therapy preparations (estradiol (E2), dihydrodydrogesterone (DHD) and tibolone) at a concentration of 10(-6) mol/l alone or combined with fulvestrant in different breast cancer cell lines, ER-positive and ER-negative."( Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Brinkhuis, M; Franke, HR; Jansen, GH; Vermes, I; Wolbers, F, 2008
)
0.56
"This in vitro study revealed clear differences in results when various hormone therapy preparations, alone or combined with fulvestrant, are added to ER-positive and ER-negative breast cancer cell lines."( Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Brinkhuis, M; Franke, HR; Jansen, GH; Vermes, I; Wolbers, F, 2008
)
0.35
"Our study demonstrated that fulvestrant, an ER antagonist used in the treatment of ER-positive breast cancer, combined with E2 and DHD or in combination with tibolone, is not compromised in its efficacy in inducing apoptosis in ER-positive breast cancer cell lines in vitro."( Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Brinkhuis, M; Franke, HR; Jansen, GH; Vermes, I; Wolbers, F, 2008
)
0.35
"To compare clinical effect of gonadotropin releasing hormone agonist (GnRH-a) alone and GnRH-a combined with low-dose dydrogesteronea and estradiol valerate on sex hormone, hypoestrogenic symptoms, quality of life and bone mineral density (BMD) in treatment of endometriosis."( [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
Chen, H; Han, Y; Hu, WG; Hua, KQ; Li, XL; Long, QQ; Zhang, SF, 2010
)
0.79
"GnRH-a combined with estrogen-progesterone regimen could relieve pain from endometriosis as effectively as GnRH-a alone and reduce hypoestrogenic symptoms and bone loss."( [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
Chen, H; Han, Y; Hu, WG; Hua, KQ; Li, XL; Long, QQ; Zhang, SF, 2010
)
0.58
"To evaluate endocrine characteristics and clinical outcomes in normal ovulatory patients undergoing controlled ovarian hyperstimulation (COH) with the use of a Duphaston and hMG protocol during in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatments in combination with frozen-thawed embryo transfer (FET) compared with the characteristics and outcomes of patients undergoing an Utrogestan and hMG protocol."( Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
Fu, Y; Ye, H; Zhu, X, 2017
)
0.46
"To evaluate the therapeutic effect of auricular acupuncture combined with dydrogesterone for threatened abortion in early pregnancy complicated with subchorionic hematoma."( [Effect on immune factors and serum CA125 in patients of threatened abortion in early pregnancy complicated with subchorionic hematoma treated with auricular acupuncture combined with dydrogesterone].
Chen, Y; Hu, S; Liao, J; Ning, Y; Wu, JM; Zhuo, YY, 2019
)
0.94
"Auricular acupuncture combined with dextroprogesterone can improve the effective rate of patients with threatened abortion in early pregnancy complicated with subchorionic hematoma, regulate immune factors, promote the hematoma absorption, and has a better synergistic effect with dextroprogesterone."( [Effect on immune factors and serum CA125 in patients of threatened abortion in early pregnancy complicated with subchorionic hematoma treated with auricular acupuncture combined with dydrogesterone].
Chen, Y; Hu, S; Liao, J; Ning, Y; Wu, JM; Zhuo, YY, 2019
)
0.71
" We compared efficacy of vaginal progesterone gel combined with oral dydrogesterone and intramuscular progesterone for HRT-FET lutein support."( Comparison of vaginal progesterone gel combined with oral dydrogesterone versus intramuscular progesterone for luteal support in hormone replacement therapy-frozen embryo transfer cycle.
Huang, L; Liu, FH; Weng, HN; Xu, H; Xu, LQ; Zhang, XQ; Zhu, XL, 2021
)
1.1
" After matching for propensity score of getting vaginal + oral treatment, a total of 208 FET cycles in the vaginal progesterone combined with oral dydrogesterone and 624 cycles in the intramuscular progesterone group were enrolled."( Comparison of vaginal progesterone gel combined with oral dydrogesterone versus intramuscular progesterone for luteal support in hormone replacement therapy-frozen embryo transfer cycle.
Huang, L; Liu, FH; Weng, HN; Xu, H; Xu, LQ; Zhang, XQ; Zhu, XL, 2021
)
1.07
"We observed similar pregnancy outcomes in both vaginal progesterone gel combined with oral dydrogesterone and intramuscular progesterone protocol."( Comparison of vaginal progesterone gel combined with oral dydrogesterone versus intramuscular progesterone for luteal support in hormone replacement therapy-frozen embryo transfer cycle.
Huang, L; Liu, FH; Weng, HN; Xu, H; Xu, LQ; Zhang, XQ; Zhu, XL, 2021
)
1.09
"To compare the efficacy of two vaginal progesterone formulations, Crinone gel or Utrogestan capsules, combined with dydrogesterone tablets, for luteal phase support in pre-implantation genetic testing (PGT) freeze-thaw embryo transfer (FET) cycles."( [Efficacy of vaginal administration of Crinone versus Utrogestan combined with oral dydrogesterone tablets for luteal support in PGT freeze-thaw embryo transfer cycles].
Chen, Z; Deng, Y; Liang, Y; Ou, Z; Sun, L, 2021
)
1.06
"Crinone gel and Utrogestan capsules combined with oral dydrogesterone have similar clinical efficacy for luteal support in PGT FET cycles."( [Efficacy of vaginal administration of Crinone versus Utrogestan combined with oral dydrogesterone tablets for luteal support in PGT freeze-thaw embryo transfer cycles].
Chen, Z; Deng, Y; Liang, Y; Ou, Z; Sun, L, 2021
)
1.09
"To discuss the effects of dydrogesterone combined with letrozole on the effectiveness, sex hormone levels, and serological indicators in patients with endometriosis."( The Effect of Letrozole Combined with Dydrogesterone for Endometriosis in China: A Meta-Analysis.
Sun, S; Xu, Z; Zhang, H; Zhong, P, 2021
)
1.19
" Our results showed that letrozole combined with dydrogesterone can significantly reduce the levels of VEGF (SMD -2."( The Effect of Letrozole Combined with Dydrogesterone for Endometriosis in China: A Meta-Analysis.
Sun, S; Xu, Z; Zhang, H; Zhong, P, 2021
)
1.15
"To explore the effect of dydrogesterone tablets combined with Zishen Yutai pills on threatened abortion in early pregnancy and pregnancy outcomes."( Effects of Dydrogesterone Tablets Combined with Zishen Yutai Pills on Threatened Abortion in Early Pregnancy and Pregnancy Outcomes.
Chen, X; Jin, Y; Qiu, X, 2022
)
1.41
"Zishen Yutai pill combined with dydrogesterone tablets is of remarkable therapeutic effect in treatment of early threatened abortion, which can significantly improve clinical symptoms and pregnancy outcomes of patients, with a high safety profile, which is worthy of clinical application."( Effects of Dydrogesterone Tablets Combined with Zishen Yutai Pills on Threatened Abortion in Early Pregnancy and Pregnancy Outcomes.
Chen, X; Jin, Y; Qiu, X, 2022
)
1.39
"To explore the impact of biomimetic electrical stimulation combined with Femoston (estradiol tablets/estradiol and dydrogesterone tablets) on pregnancy rate and endometrium characteristics (endometrial thickness and type) in patients with infertility and a thin endometrium."( Impact of biomimetic electrical stimulation combined with Femoston on pregnancy rate and endometrium characteristics in infertility patients with thin endometrium: a prospective observational study.
Lu, J; Shabiti, Y; Tuohuti, R; Wufuer, S; Yun, T, 2023
)
1.12
" The patients received Femoston alone (Femoston group) or Femoston combined with biomimetic electrical stimulation (electrotherapy group)."( Impact of biomimetic electrical stimulation combined with Femoston on pregnancy rate and endometrium characteristics in infertility patients with thin endometrium: a prospective observational study.
Lu, J; Shabiti, Y; Tuohuti, R; Wufuer, S; Yun, T, 2023
)
0.91
"The results suggest the possibility that biomimetic electrical stimulation combined with Femoston could improve endometrial type and thickness in patients with infertility and thin endometrium compared with Femoston alone, but the pregnancy rate showed no significant improvement."( Impact of biomimetic electrical stimulation combined with Femoston on pregnancy rate and endometrium characteristics in infertility patients with thin endometrium: a prospective observational study.
Lu, J; Shabiti, Y; Tuohuti, R; Wufuer, S; Yun, T, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" Among those is dydrogesterone, an oral retrosteroid with a structure closely related to that of progesterone yet with a greater bioavailability and higher selectivity for the progesterone receptor."( Dydrogesterone use in early pregnancy.
Mirza, FG; Patki, A; Pexman-Fieth, C, 2016
)
2.22
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

No influence of dydrogesterone dosage was found. Cycle control was good and the mean day of onset of bleeding occurred on or after day 11. A dose-response relation was seen in the induction of oestradiol-17 beta and isocitrate dehydrogenase activities.

ExcerptRelevanceReference
" Cycle control was good and the mean day of onset of bleeding occurred on or after day 11 of the dydrogesterone dosage by the 5th cycle."( Dydrogesterone to oppose the 100 mg oestradiol implant.
Greenwood, PA; Jesinger, DK, 1991
)
1.94
" Acceptable bleeding patterns were seen in both dosage groups."( A first study to compare two dosages of dydrogesterone in opposing the 50 mg oestradiol implant.
Barlow, DH; Collins, SA; Leather, A; Pryse-Davies, J; Rees, M; Studd, JW, 1991
)
0.55
" It has been used for a few years in the treatment of benign breast diseases at a dosage of 200-800 mg daily."( [Danazol in treatment of cystic mastopathy].
Radivojevic, K, 1991
)
0.28
" A dose-response relation was seen in the induction of oestradiol-17 beta and isocitrate dehydrogenase activities; hyperphysiological values were observed with 20 mg of dydrogesterone daily."( Effects of dydrogesterone on the oestrogenized postmenopausal endometrium.
King, RJ; Lane, G; Pryse-Davies, J; Ryder, TA; Siddle, NC; Whitehead, MI, 1986
)
0.86
" Daily dosage was 20-30 mg, higher dosage for those with exceeded optimal body weight."( Glandular cystic hyperplasia of the endometrium in the perimenopausal years.
Hren-Bozic, M; Meden-Vrtovec, H,
)
0.13
" Greater drop-out rate and greater incidence of side effects attributed to oestrogen in higher dosage group."( A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome.
Holland, EF; Smith, RN; Studd, JW; Zamblera, D, 1995
)
0.29
" No influence of dydrogesterone dosage was found."( Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.
Jakobs, C; Kenemans, P; Mijatovic, V; Netelenbos, C; Peters-Muller, ER; Popp-Snijders, C; van der Mooren, MJ, 1998
)
0.88
" dosing with 100 mg kg-1 once a week for 6 successive weeks, the values of the number and area of gamma-glutamyltranspeptidase-positive foci were, as compared to controls, 15."( Induction of micronuclei and of enzyme-altered foci in the liver of female rats exposed to progesterone and three synthetic progestins.
Allavena, A; Brambilla, G; De Pascalis, CR; Ghia, M; Martelli, A; Mereto, E; Orsi, P, 1998
)
0.3
" Adjustment of intranasal dosage was permitted from week 14 on."( Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.
Bergeron, C; Chevallier, O; Christiansen, C; Colau, JC; Gangar, K; Kenemans, P; Mattsson, LA; Palacios, S; Von Holst, T, 2000
)
0.31
"5 mg dydrogesterone dosage (93% in the 1/2."( Endometrial safety of continuous combined hormone replacement therapy with 17beta-oestradiol (1 or 2 mg) and dydrogesterone.
Bergeron, C; Ferenczy, A, 2001
)
1.04
" Femoston Low is in agreement with the recent recommendations for menopausal hormone replacement therapy, which give the preference to low dosage therapy whenever possible."( [Medication of the month. Femoston Low (0.5 mg estradiol plus 2.5 mg dydrogesterone) for menopausal hormonal replacement therapy].
Gaspard, U; Scheen, AJ, 2011
)
0.6
" Randomised controlled studies are needed to determine the optimal dosage of dydrogesterone for luteal phase support in ARTs."( Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques.
Faisal, F; Nadarajah, R; Rajesh, H; Wong, KY; Yu, SL, 2017
)
0.95
" However, the use of MPA may lead to stronger pituitary suppression and thus may require a higher dosage of hMG and a longer duration of ovarian stimulation than that of conventional ovarian stimulation protocol."( New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
Ai, A; Chang, HY; Gao, H; Kuang, Y; Liu, Y; Long, H; Lyu, Q; Quan, X; Yu, S; Zhu, J, 2018
)
0.81
" Progesterone supplements are believed to reduce the rate of preterm labor, but formulation, type of administration, and dosage varies in different studies."( Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
Alizadeh, F; Mahmoudinia, M; Mirteimoori, M; Niroumand, S; Pourali, L, 2022
)
1.05
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
progestinA synthetic progestogen.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency43.64860.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency61.14290.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency6.51040.004110.890331.5287AID504466
TDP1 proteinHomo sapiens (human)Potency9.38210.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency11.23710.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency3.13370.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743036; AID743040; AID743053; AID743054; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency2.37100.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency0.01330.000417.946075.1148AID1346784; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency2.75400.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.86380.000214.376460.0339AID720691; AID720692; AID720719
retinoid X nuclear receptor alphaHomo sapiens (human)Potency24.85000.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.15980.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency26.60320.005428.02631,258.9301AID1346982
GVesicular stomatitis virusPotency13.80290.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency15.48710.00108.379861.1304AID1645840
67.9K proteinVaccinia virusPotency0.35480.00018.4406100.0000AID720580
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency7.07950.10009.191631.6228AID1346983
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency9.20000.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency9.57310.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency16.08220.000627.21521,122.0200AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency31.62280.004611.374133.4983AID624297
Interferon betaHomo sapiens (human)Potency13.80290.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency14.29990.002319.595674.0614AID651631
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.70790.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (168)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (50)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346851Human Progesterone receptor (3C. 3-Ketosteroid receptors)2011Steroids, May, Volume: 76, Issue:6
Selectivity and potency of the retroprogesterone dydrogesterone in vitro.
AID1346851Human Progesterone receptor (3C. 3-Ketosteroid receptors)2003Maturitas, Dec-10, Volume: 46 Suppl 1Classification and pharmacology of progestins.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (569)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990142 (24.96)18.7374
1990's79 (13.88)18.2507
2000's121 (21.27)29.6817
2010's132 (23.20)24.3611
2020's95 (16.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 101.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index101.61 (24.57)
Research Supply Index6.65 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index185.72 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (101.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials173 (28.83%)5.53%
Reviews51 (8.50%)6.00%
Case Studies25 (4.17%)4.05%
Observational8 (1.33%)0.25%
Other343 (57.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (66)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Tualang Honey and Hormonal Replacement Therapy (HRT) on Safety Profiles Among Postmenopausal Women [NCT01300676]Phase 2/Phase 379 participants (Actual)Interventional2009-03-31Completed
Which Luteal Support in Frozen-Thawed Embryo Transfer Cycles: A Randomized Controlled Trial [NCT03948022]Phase 4151 participants (Actual)Interventional2021-06-30Completed
Progesterone Primed Ovarian Stimulation Protocol (PPOS) VS GnRH Antagonist Protocol in Patients With Expected High Ovarian Response Undergoing ICSI Cycles: a Prospective Randomized Controlled Trial [NCT05951400]Phase 2/Phase 3200 participants (Anticipated)Interventional2023-08-20Not yet recruiting
Oral Dydrogesterone Versus Vaginal Progesterone Gel in the Luteal Phase Support: Randomized Controlled Trial [NCT01178931]853 participants (Actual)Interventional2010-10-31Completed
Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Phase Support in In Vitro Fertilisation (IVF)/ IntraCytoplasmic Sperm Injection (ICSI): Pharmacokinetics and the Impact on the Endometrium, the Microbiota of the Genital Tract and the P [NCT03677336]Phase 430 participants (Actual)Interventional2019-05-01Completed
The Effect of Estrogen in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis [NCT03620929]Phase 4186 participants (Anticipated)Interventional2018-08-13Enrolling by invitation
Prospective One-arm Cohort Study of Dydrogesterone in the Treatment of Endometrial Polyps [NCT03790215]Phase 460 participants (Actual)Interventional2019-02-01Completed
A Prospective Randomized Study of the Impact of Hormonal Monitoring and Progesterone Supplementation Adjustment on Outcome of Programmed Thawed Embryo Transfer Cycles [NCT05189145]600 participants (Actual)Interventional2019-10-01Completed
Comparison of Reproductive Outcomes After Progestin-primed Ovarian Stimulation With Dydrogesterone Versus Cetrorelix to Inhibit Spontaneous Ovulation in Oocyte Donation [NCT05577806]202 participants (Anticipated)Observational2017-01-01Completed
Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders [NCT04537078]Phase 390 participants (Actual)Interventional2020-09-01Completed
A Double Blinded Randomized Controlled Trial of Early Use of Oral Progesterone in All Women for Prevention of Preterm Delivery in Singleton Pregnancy (SINPRO Study) [NCT03428685]Phase 2/Phase 31,714 participants (Anticipated)Interventional2019-01-15Recruiting
Observational Open-Label Multicenter Study of Real Clinical Practice to Evaluate the Effects of Hormonal Therapy With Oral Dydrogesterone for Treatment of Confirmed Endometriosis (ORCHIDEA) [NCT03690765]350 participants (Actual)Observational2018-09-27Completed
Dydrogesterone Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in Hormone Replacement Therapy (HRT) Frozen Embryo Transfer (FET) Cycles. [NCT04758871]Phase 4150 participants (Actual)Interventional2021-10-01Active, not recruiting
Dydrogesterone Primed Ovarian Stimulation Versus Fixed Gonadotropin Releasing Hormone Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: A Randomized Controlled Trial [NCT05847283]730 participants (Anticipated)Interventional2023-06-22Recruiting
The Effect of Different Types of Progestin on Sleeping of Menopausal Women [NCT02086032]100 participants (Actual)Interventional2014-01-31Completed
Duphaston® Tablets 5 mg - A Survey on Efficacy and Safety in Patients With Endometriosis [NCT02921763]60 participants (Actual)Observational [Patient Registry]2016-08-23Completed
A Randomized Double Blind Controlled Comparison of Oral Dydrogesterone as Luteal Phase Support in Natural Cycle Frozen-thawed Embryo Transfer [NCT03859921]Phase 3716 participants (Anticipated)Interventional2021-07-01Recruiting
Oral Dydrogesterone as Adjunctive Therapy in the Management of Preterm Labor: A Randomized, Double Blinded, Placebo-controlled Trial [NCT03935152]Phase 448 participants (Actual)Interventional2019-05-11Completed
A Prospective, Multicenter, Randomized, Open-label, Comparative Study in Three Parallel Groups to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone (Femoston® 1 or Femoston® 2, Coated Tablets) and the Combination [NCT05156814]Phase 4150 participants (Anticipated)Interventional2021-11-29Recruiting
The Efficacy and Safety of the Dried Biological Amnion Graft Following Hysteroscopic Lysis for the Prevention of Postoperative Adhesions in Patients With Intrauterine Adhesions [NCT02496052]300 participants (Anticipated)Interventional2013-01-31Recruiting
The Effect of Dydrogesterone on Sexual Function in Women With Endometriosis [NCT04287205]79 participants (Actual)Interventional2019-04-20Completed
Comparison Between Effects of Dydrogesterone, Cetrorelix Acetate and Triptorelin on Intra Cytoplasmic Sperm Injection Outcomes [NCT05972902]Phase 3387 participants (Anticipated)Interventional2023-07-15Recruiting
A Randomized, Double Blinded, Placebo Controlled Trial of Oral Progestogen Supplementation in the Prevention of Recurrent Uterine Contraction in Preterm Labor [NCT02262481]48 participants (Actual)Interventional2014-08-31Completed
Intramuscular 17Alpha-hydroxyprogestrone, Progesterone Suppositories and Dydrogesterone Tablets in Preventing Preterm Labor [NCT03537287]Phase 2140 participants (Anticipated)Interventional2016-07-31Recruiting
Randomized, Controlled Trial to Assess the Efficacy of Disposable Balloon Uterine Stent Combined With Estrogen or Dried Biological Amnion Graft for the Therapy of Uterine Adhesion [NCT03346317]100 participants (Anticipated)Interventional2017-11-16Recruiting
Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles [NCT05112692]200 participants (Anticipated)Interventional2021-11-30Not yet recruiting
Multicenter Open Prospective Comparative Non-interventional Study of Therapy for Threatened Miscarriage With Medicinal Products Utrogestan, 200 mg Capsules (Besins Healthcare SA, Belgium), and Duphaston, 10 mg Coated Tablets (Abbott Healthcare Products B. [NCT03309735]1,241 participants (Actual)Observational2017-10-16Completed
Role of Serum Progesterone and Doppler Ultrasound in Prediction of Pregnancy Outcome in Women With Recurrent Unexplained Abortion [NCT03267771]Phase 450 participants (Anticipated)Interventional2017-10-01Not yet recruiting
A Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Women With Threatened Miscarriage in the First Trimester [NCT02128685]Phase 3406 participants (Actual)Interventional2016-03-31Completed
A Randomized, Controlled Trial of Cyclosporin A for Women With Unexplained Recurrent Miscarriage [NCT02706470]Phase 2/Phase 3384 participants (Anticipated)Interventional2016-05-31Not yet recruiting
Role Of Dydrogesterone Towards Oocyte and Embryo Quality in Polycystic Ovarian Syndrome (PCOS) [NCT04175990]Phase 1155 participants (Actual)Interventional2018-05-10Completed
How to Rescue Hormonal Replacement Frozen Embryo Transfer Cycle With Low Serum Progesterone? A Randomized Control Trial. [NCT05758064]Phase 2/Phase 3120 participants (Anticipated)Interventional2023-01-01Recruiting
Endometrial Safety of a Low Dose Continuous Combined 17 -Estradiol/Dydrogesterone Hormone Replacement Regimen (E2 0.5 mg/ D 2.5 mg) in Postmenopausal Women - A One-Year, Open Label, Multi-Center Study [NCT00160316]Phase 3454 participants (Actual)Interventional2005-04-30Completed
A Randomized, Placebo-Controlled, Double-Blind, Multi-National Study to Demonstrate Efficacy of Continuous Combined 0.5 mg Estradiol and 2.5 mg Dydrogesterone in the Treatment of Vasomotor Symptoms in Postmenopausal Women in Comparison to Placebo Over 3 M [NCT00251082]Phase 3391 participants (Actual)Interventional2005-12-31Completed
Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia [NCT03675139]Phase 3471 participants (Actual)Interventional2019-02-26Completed
Micronized Progesterone Versus Micronized Progesterone Plus Dydrogesterone for Luteal Phase Support in Frozen - Thawed Transfer: a Prospective Cohort Study [NCT03998761]1,364 participants (Actual)Interventional2019-06-26Completed
Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy [NCT02620345]Phase 422 participants (Actual)Interventional2010-01-31Completed
Oral Dydrogesterone Treatment During the First Trimester of Pregnancy in Women With Recurrent Miscarriage: A Double-Blind, Prospectively Randomized, Placebo-Controlled, Parallel Group Trial [NCT00193674]Phase 371 participants (Actual)Interventional2003-09-30Completed
Didroxyprogesterone Promotes Postoperative Natural Pregnancy in Infertile Patients With Mild and Moderate Endometriosis [NCT05467852]Phase 3300 participants (Anticipated)Interventional2022-12-10Not yet recruiting
A Randomized Controlled Study of Progesterone Primed Ovarian Stimulation Protocol Versus Antagonist Protocol for PCO Patients in Intracytoplasmic Sperm Injection Cycles [NCT05847660]210 participants (Anticipated)Interventional2023-06-01Not yet recruiting
A Twelve 28-Day Cycles, Multicenter, Prospective, Randomized, Open, Blinded Endpoint, Parallel Group Study Comparing the Effect on Breast and Cardiovascular Metabolic Markers of Continuously Combined 17β-Estradiol/Dydrogesterone and Tibolone in Postmenopa [NCT00145522]Phase 4135 participants (Actual)Interventional2005-11-30Completed
A Double-Blind, Double-Dummy, Randomized, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertil [NCT01850030]Phase 31,070 participants (Actual)Interventional2013-08-31Completed
Effects of Co-treatment With Aromatase Inhibitor or Progestin on Endometrial abv3-integrin Expressions in Women With Recurrent Implantation Failure [NCT05437471]39 participants (Actual)Interventional2020-01-01Completed
A Randomized, Open-label, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II) [NCT02491437]Phase 31,034 participants (Actual)Interventional2015-07-31Completed
Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Patients With Polycystic Ovary Syndrome Undergoing Intra-Cytoplasmic Sperm Injection [NCT05751681]79 participants (Anticipated)Interventional2023-02-20Recruiting
Comparison of Cetrorelix, Medroxyprogesterone Acetate and Dydrogesterone for Preventing Premature Ovulation in Ovarian Stimulation Cycles [NCT05767086]297 participants (Anticipated)Interventional2023-03-15Recruiting
Effectiveness of Treatment With Additional Dydrogesterone (Duphaston) to the Standard Luteal Phase Support After Fresh Embryo Transfer: a Prospective Randomized Controlled Trial. [NCT04408144]300 participants (Anticipated)Interventional2022-04-01Not yet recruiting
"The Effect of Pretreatment With Dydrogesterone Vs Combined Estradiol Valerate and Dydrogestrone on Clinical Pregnancy Outcome of ICSI in PCOS Patients" [NCT05300841]Early Phase 1500 participants (Anticipated)Interventional2022-05-01Not yet recruiting
An Open-labeled Prospective Randomized Controlled Trial on the Effect of Different Regimens for Luteal Phase Support on Pregnancy Outcomes in Patients With Idiopathic Hypogonadotropic Hypogonadism [NCT05569577]46 participants (Anticipated)Interventional2021-01-01Recruiting
The Efficacy of Progestins in Treatment of Functional Ovarian Cyst [NCT03456570]Early Phase 190 participants (Anticipated)Interventional2018-05-01Not yet recruiting
Comparison of the Efficacy of Oral Progesterone and Vaginal Progesterone After Tocolytic Therapy in Threatened Preterm Labor [NCT02989519]Phase 3231 participants (Actual)Interventional2015-08-31Completed
A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the Progestin-primed Ovarian Stimulation Protocol and the GnRH Antagonist Protocol in Patients Undergoing PGT-A [NCT04414748]Phase 3400 participants (Anticipated)Interventional2020-06-10Recruiting
A Randomized Comparison of the Live Birth Rate Between the Progestin-primed Ovarian Stimulation Protocol and the Gonadotrophin Releasing Hormone Antagonist Protocol in Patients Undergoing in Vitro Fertilization [NCT03680053]784 participants (Anticipated)Interventional2020-04-10Recruiting
The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss [NCT02990403]Phase 4500 participants (Anticipated)Interventional2014-10-31Recruiting
Oral Dydrogesterone vs. Vaginal Micronized Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer: a Non-inferiority Randomized Clinical Trial [NCT03832699]100 participants (Anticipated)Interventional2019-03-01Recruiting
Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone: a Randomized Cross Over Pilot Trial [NCT05521828]50 participants (Anticipated)Interventional2023-04-01Recruiting
Oral Progesterone for Prevention of Miscarriage in Threatened Abortion: a Randomized, Double-blinded, Placebo-controlled Trial [NCT04788108]Phase 4100 participants (Actual)Interventional2021-08-01Completed
A Randomized Control Trial to Compare the Live Birth Rate Between the Progestin-primed Ovarian Stimulation Protocol and the GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response Undergoing IVF [NCT04414761]Phase 3784 participants (Actual)Interventional2020-06-04Completed
A Multi-center Clinical Study on the Efficacy and Safety of Kuntai Capsule Alone and in Combination With Hormones in the Treatment of Early-onset Hypoovarian Function [NCT05021094]Phase 4120 participants (Anticipated)Interventional2021-10-22Recruiting
Randomized, Controlled Trial to Assess the Efficacy of Disposable Balloon Uterine Stent Combined With Estrogen or Dried Biological Amnion Graft in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis [NCT03329898]200 participants (Anticipated)Interventional2017-10-31Recruiting
Comparison of Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles: a Randomized Controlled Trial [NCT04124913]Phase 4140 participants (Anticipated)Interventional2019-01-02Recruiting
The Effect and Risk of Conjugated Estrogens Combined With Different Types of Progestin in the Treatment of Menopause Syndrome During Window Phase [NCT03436303]Phase 4120 participants (Anticipated)Interventional2014-02-01Active, not recruiting
Multicenter Open-Label Observational Program to Research on Predictors of Pregnancy Rate in Assisted Reproductive Technology in the Russian Population and Kazakhstan Population According to Actual International and National Guidelines (IRIS) [NCT04249297]1,150 participants (Anticipated)Observational2020-03-03Recruiting
Comparison of Crinone ® Versus Combination Medication for Luteal Phase Support on the Ongoing Pregnancy Rate of Frozen-thawed Cycle in Chinese Population a Randomized, Interventional, Open-label, Phase IV, Single Center, Pilot Study (ACCESS) [NCT03858049]Phase 4172 participants (Actual)Interventional2019-05-31Terminated(stopped due to The trend in LPS treatment tends to increase the dosage of progesterone in FET-HRT, this study was designed 5 years ago.)
The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study [NCT05135013]200 participants (Anticipated)Observational2021-11-16Not yet recruiting
Randomized, Controlled Trial to Assess the Efficacy of Estrogen Therapy Combined With Disposable Balloon Uterine Stent and Dried Biological Amnion Graft in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis [NCT03351205]100 participants (Anticipated)Interventional2017-11-21Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01850030 (4) [back to overview]Percentage of Participants With a Successful Completion of Pregnancy
NCT01850030 (4) [back to overview]Gender of the Newborn
NCT01850030 (4) [back to overview]Percentage of Participants Being Pregnant as Measured by the Presence of Fetal Heart Beats at 12 Weeks´Gestation Using Transvaginal Ultrasound
NCT01850030 (4) [back to overview]Percentage of Participants Being Pregnant as Measured by the Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer
NCT02491437 (4) [back to overview]Physical Examination Newborn (Number of Delivered Newborns That Are Male or Female)
NCT02491437 (4) [back to overview]Positive Pregnancy Test Rate (Percentage of Participants With a Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer)
NCT02491437 (4) [back to overview]Percentage of Participants With Presence of Fetal Heart Beats at 12 Week's Gestation Determined by Transvaginal Ultrasound
NCT02491437 (4) [back to overview]Rate of Successful Completion of Pregnancy (Percentage of Participants With a Live Birth)
NCT02921763 (12) [back to overview]Change Over Time in Visual Analogue Scale (VAS) for Dysmenorrhea, Change Rate From Baseline (%)
NCT02921763 (12) [back to overview]Change Over Time in Visual Analogue Scale (VAS) for Dysmenorrhea, Difference From Baseline
NCT02921763 (12) [back to overview]Volume of Ovarian Chocolate Cyst Over Time (If There Are Two or More Cysts, a Total Volume), % Change From Baseline
NCT02921763 (12) [back to overview]Volume of Ovarian Chocolate Cyst Over Time (If There Are Two or More Cysts, a Total Volume), Absolute Change From Baseline
NCT02921763 (12) [back to overview]Change in the Volume of Ovarian Chocolate Cyst (If There Are Two or More Cysts, a Total Volume)
NCT02921763 (12) [back to overview]Volume of Ovarian Chocolate Cyst Over Time (If There Are Two or More Cysts, a Total Volume)
NCT02921763 (12) [back to overview]Change in Serum CA125
NCT02921763 (12) [back to overview]Change in Serum CA125, Change Rate From Baseline (%)
NCT02921763 (12) [back to overview]Change in Serum CA125, Difference From Baseline
NCT02921763 (12) [back to overview]Change Over Time in Dysmenorrhea Score (Total of the Dysmenorrhea Severity Score and the Analgesic Use Score)
NCT02921763 (12) [back to overview]Change Over Time in Dysmenorrhea Score (Total of the Dysmenorrhea Severity Score and the Analgesic Use Score), Difference From Baseline
NCT02921763 (12) [back to overview]Change Over Time in Visual Analogue Scale (VAS) for Dysmenorrhea
NCT04537078 (14) [back to overview]Assessing the Difference Between the Follicular Phase of the Progestin Primed Double Stimulation Protocol and the First Round of the Conventional GnRH Antagonist Protocol Regarding the Number of M2 Oocytes Retrieved .
NCT04537078 (14) [back to overview]Assessing the Difference Between the Follicular Phase of the Progestin Primed Double Stimulation Protocol and the First Round of the Conventional GnRH Antagonist Protocol Regarding the Resultant Embryos Number.
NCT04537078 (14) [back to overview]the Clinical Pregnancy Rate.
NCT04537078 (14) [back to overview]the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Fertilization Rate.
NCT04537078 (14) [back to overview]the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Number of M2 Oocytes Retrieved
NCT04537078 (14) [back to overview]the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Resultant Embryos Number
NCT04537078 (14) [back to overview]the Resultant Embryos Number
NCT04537078 (14) [back to overview]the Number of M2 Oocytes Retrieved
NCT04537078 (14) [back to overview]the Implantation Rate
NCT04537078 (14) [back to overview]the Fertilization Rate
NCT04537078 (14) [back to overview]the Difference in the Ongoing Pregnancy Rate in Both Protocols.
NCT04537078 (14) [back to overview]the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Total Dosage of Gonadotropins Used in the Controlled Ovarian Hyperstimulation
NCT04537078 (14) [back to overview]the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Total Days of Controlled Ovarian Hyperstimulation
NCT04537078 (14) [back to overview]Assessing the Difference Between the Follicular Phase of the Progestin Primed Double Stimulation Protocol and the First Round of the Conventional GnRH Antagonist Protocol Regarding the Fertilization Rate.

Percentage of Participants With a Successful Completion of Pregnancy

Incidence of live births and healthy newborns (NCT01850030)
Timeframe: After delivery (about 9 months after IVF)

,
Interventionpercentage of participants (Number)
Live birth rateHealthy newborn rate
Dydrogesterone 30 mg34.632
Micronized Progesterone 600 mg29.827.7

[back to top]

Gender of the Newborn

was recorded and collected for Newborn (NCT01850030)
Timeframe: After delivery (about 9 months after IVF)

,
Interventionnumber of newborns (Number)
Gender maleGender female
Dydrogesterone 30 mg12093
Micronized Progesterone 600 mg8870

[back to top]

Percentage of Participants Being Pregnant as Measured by the Presence of Fetal Heart Beats at 12 Weeks´Gestation Using Transvaginal Ultrasound

Percentage of participants being pregnant as measured by the presence of fetal heart beats at 12 weeks´gestation using transvaginal ultrasound (NCT01850030)
Timeframe: 12 weeks´ gestation (at visit 6)

Interventionpercentage of participants (Number)
Dydrogesterone 30 mg37.6
Micronized Progesterone 600 mg33.1

[back to top]

Percentage of Participants Being Pregnant as Measured by the Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer

Percentage of participants being pregnant as measured by the positive biochemical pregnancy test on Day 14 after embryo transfer (NCT01850030)
Timeframe: Day 14 after embryo transfer

Interventionpercentage of participants (Number)
Dydrogesterone 30 mg47.1
Micronized Progesterone 600 mg45.5

[back to top]

Physical Examination Newborn (Number of Delivered Newborns That Are Male or Female)

The gender (number of delivered newborns that are male or female) (NCT02491437)
Timeframe: After delivery (about 9 months after IVF)

,
Interventionnumber of newborns (Number)
Gender maleGender female
Crinone 8% Intravaginal Progesterone Gel 90 mg9593
Dydrogesterone Tablets 3x10 mg105100

[back to top]

Positive Pregnancy Test Rate (Percentage of Participants With a Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer)

Positive biochemical pregnancy test on Day 14 after embryo transfer (NCT02491437)
Timeframe: Day 14 after embryo transfer

Interventionpercentage of participants (Number)
Dydrogesterone Tablets 3x10 mg47.4
Crinone 8% Intravaginal Progesterone Gel 90 mg43.8

[back to top]

Percentage of Participants With Presence of Fetal Heart Beats at 12 Week's Gestation Determined by Transvaginal Ultrasound

Pregnancy rate defined as the presence of fetal heart beats at 12 weeks' gestation determined by transvaginal ultrasound. (NCT02491437)
Timeframe: 12 weeks´ gestation

Interventionpercentage of participants (Number)
Dydrogesterone Tablets 3x10 mg38.7
Crinone 8% Intravaginal Progesterone Gel 90 mg35.0

[back to top]

Rate of Successful Completion of Pregnancy (Percentage of Participants With a Live Birth)

Live birth rate (percentage of participants with a live birth) (NCT02491437)
Timeframe: After delivery (about 9 months after IVF)

Interventionpercentage of participants (Number)
Dydrogesterone Tablets 3x10 mg34.4
Crinone 8% Intravaginal Progesterone Gel 90 mg32.5

[back to top]

Change Over Time in Visual Analogue Scale (VAS) for Dysmenorrhea, Change Rate From Baseline (%)

"A straight line with a total length of 10 cm was prepared. This straight line was defined as no pain at the left end and Worst pain imaginable at the right end.~The cases marked the degree of pain on this straight line at each time point, and the length (cm) from the left end of the line (0) was measured.~The minimum value of VAS is 0 cm (no pain) and the maximum value is 10 cm (Worst pain imaginable).~The change rate from baseline were calculated on an individual basis and these were totalled and means ± SD calculated." (NCT02921763)
Timeframe: Baseline, 1 month, 2 months, 3 months, 4 months, and 5 months.

Interventionpercent change (Mean)
Cycle 1-9.23
Cycle 2-33.97
Cycle 3-38.01
Cycle 4-41.24
Cycle 5-35.75

[back to top]

Change Over Time in Visual Analogue Scale (VAS) for Dysmenorrhea, Difference From Baseline

"A straight line with a total length of 10 cm was prepared. This straight line was defined as no pain at the left end and Worst pain imaginable at the right end.~The cases marked the degree of pain on this straight line at each time point, and the length (cm) from the left end of the line (0) was measured.~The minimum value of VAS is 0 cm (no pain) and the maximum value is 10 cm (Worst pain imaginable).~The units on a scale is cm. The difference from baseline were calculated on an individual basis and these were totalled and means ± SD calculated." (NCT02921763)
Timeframe: Baseline, 1 month, 2 months, 3 months, 4 months, and 5 months.

Interventioncm (Mean)
Cycle 1-0.93
Cycle 2-1.61
Cycle 3-1.98
Cycle 4-1.94
Cycle 5-1.52

[back to top]

Volume of Ovarian Chocolate Cyst Over Time (If There Are Two or More Cysts, a Total Volume), % Change From Baseline

"The % change from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.~For the mean value of the % changes shown here, the mean value of the % changes of the cases that could be measured at each time point is calculated. In other words, of the 57 cases with the volume value of baseline, Cycle 3 calculates the mean value of the % change in 39 cases with the volume value at this time, and Cycle 5 calculates the mean value of the % change in 40 cases with the volume value at this time.~The remaining 18 cases are excluded from this calculation because there is no volume value for Cycle 3 and the % change from baseline cannot be calculated. The same applies to the 17 cases of Cycle 5.~For this reason, these values cannot be calculated directly from the volume mean value at each time point shown in the result measurement 2." (NCT02921763)
Timeframe: Before treatment initiation (baseline), 3 months, and 5 months.

Interventionpercent change (Mean)
Cycle 33.97
Cycle 5-6.40

[back to top]

Volume of Ovarian Chocolate Cyst Over Time (If There Are Two or More Cysts, a Total Volume), Absolute Change From Baseline

"The absolute change from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.~For the mean value of the absolute changes shown here, the mean value of the absolute changes of the cases that could be measured at each time point is calculated. In other words, of the 57 cases with the volume value of baseline, Cycle 3 calculates the mean value of the absolute change in 39 cases with the volume value at this time, and Cycle 5 calculates the mean value of the absolute change in 40 cases with the volume value at this time.~The remaining 18 cases are excluded from this calculation because there is no volume value for Cycle 3 and the absolute change from baseline cannot be calculated. The same applies to the 17 cases of Cycle 5.~For this reason, these values cannot be calculated directly from the volume mean value at each time point shown in the result measurement 2." (NCT02921763)
Timeframe: Before treatment initiation (baseline), 3 months, and 5 months.

Interventioncm^3 (Mean)
Cycle 30.04
Cycle 58.48

[back to top]

Change in the Volume of Ovarian Chocolate Cyst (If There Are Two or More Cysts, a Total Volume)

"In measurement of ovarian chocolate cyst, on a section visualizing the maximum diameter, two radial directions, namely the maximum diameter (D1) and maximum diameter (D2) orthogonal to D1, will be measured. A chocolate cyst of the ovary will be deemed as a spheroid, and its volume will be calculated using the following formula: [(D1 + D2) × 1/2]3 × 0.52 (π = 3.1). If there are two or more chocolate cysts of the ovary, similarly, two radial directions (D1 and D2) of each cyst will be measured. Also, each of their volumes will be calculated in the same manner.~The change rate within ±15% from the total volume measured before treatment was defined as unchanged, and the rate out of this range was defined as decreased or increased." (NCT02921763)
Timeframe: Before treatment initiation (baseline), 3 months, and 5 months.

InterventionParticipants (Count of Participants)
DecreasedUnchangedIncreased
Dydrogesterone261313

[back to top]

Volume of Ovarian Chocolate Cyst Over Time (If There Are Two or More Cysts, a Total Volume)

In measurement of ovarian chocolate cyst, on a section visualizing the maximum diameter, two radial directions, namely the maximum diameter (D1) and maximum diameter (D2) orthogonal to D1, will be measured. A chocolate cyst of the ovary will be deemed as a spheroid, and its volume will be calculated using the following formula: [(D1 + D2) × 1/2]3 × 0.52 (π = 3.1). If there are two or more chocolate cysts of the ovary, similarly, two radial directions (D1 and D2) of each cyst will be measured. Also, each of their volumes will be calculated in the same manner. (NCT02921763)
Timeframe: Before treatment initiation (baseline), 3 months, and 5 months.

Interventioncm^3 (Mean)
Cycle -1Cycle 3Cycle 5
Dydrogesterone45.7651.9760.27

[back to top]

Change in Serum CA125

"CA-125 is a glycoprotein antigen recognized by the monoclonal antibody OC125 made against ovarian cancer cell cultures.~Serum CA125 is commonly used as a tumor marker for ovarian cancer, and since it increases at a high rate in endometriosis, it has an aspect of being used as a diagnostic aid for endometriosis.~There are many reports that the normal value of serum CA-125 is 35 U/mL or less.~The test was performed during a non-menstruation period, as serum CA-125 levels are high during the menstrual period." (NCT02921763)
Timeframe: Baseline, and 5 months.

InterventionU/mL (Mean)
Cycle -155.66
Cycle 547.52

[back to top]

Change in Serum CA125, Change Rate From Baseline (%)

"The change rate from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.~For the mean value of the change rate shown here, the mean value of the change rate of the cases that could be measured at each time point is calculated.~In other words, of the 56 cases with baseline serum CA125, cycle 5 can only calculate the change rate in 32 cases with serum CA125 at this point.~The mean change rate between cycle 5 and baseline in these 32 cases is shown here.~The remaining 24 cases in baseline are excluded from this calculation because they do not have serum CA125 measurements in Cycle 5.~For this reason, these values cannot be calculated directly from the serum CA125 mean value at each time point shown in the result measurement 7." (NCT02921763)
Timeframe: Baseline, and 5 months.

Interventionpercent change (Mean)
Cycle 538

[back to top]

Change in Serum CA125, Difference From Baseline

"The difference from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.~For the mean value of the difference shown here, the mean value of the difference of the cases that could be measured at each time point is calculated.~In other words, of the 56 cases with baseline serum CA125, cycle 5 can only calculate the difference in 32 cases with serum CA125 at this point.~The mean difference between cycle 5 and baseline in these 32 cases is shown here.~The remaining 24 cases in Baseline are excluded from this calculation because they do not have serum CA125 measurements in Cycle 5.~For this reason, these values cannot be calculated directly from the serum CA125 mean value at each time point shown in the result measurement 7." (NCT02921763)
Timeframe: Baseline, and 5 months.

InterventionU/mL (Mean)
Cycle 5-6.47

[back to top]

Change Over Time in Dysmenorrhea Score (Total of the Dysmenorrhea Severity Score and the Analgesic Use Score)

"The dysmenorrhea score is the sum of the dysmenorrhea severity score and the analgesic use score. Shown as the mean value for the number of cases at each time point.~A dysmenorrhea severity score is defined as follows. None: Score 0, Rarely interfering with work (study and house work): Score 1, Interfering with work (study and house work) requiring lying down to rest: Score 2, Being confined to bed for 1 day, being unable to work (study and house work): Score 3.~A analgesic use score is defined as follows. None: Score 0, An analgesic was used for a day during the last (or current) menstruation period: Score 1, An analgesic was used for 2 days during the last (or current) menstruation period: Score 2, An analgesic was used for 3 days during the last (or current) menstruation period: Score 3 The minimum dysmenorrhea score is 0 and the maximum dysmenorrhea score is 6." (NCT02921763)
Timeframe: Baseline, 1 month, 2 months, 3 months, 4 months, and 5 months.

Interventionscore on a scale (Mean)
Cycle -12.30
Cycle 11.75
Cycle 21.31
Cycle 31.12
Cycle 41.00
Cycle 51.05

[back to top]

Change Over Time in Dysmenorrhea Score (Total of the Dysmenorrhea Severity Score and the Analgesic Use Score), Difference From Baseline

"The dysmenorrhea score is the sum of the dysmenorrhea severity score and the analgesic use score.~The difference from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.~A dysmenorrhea severity score is defined as follows. None: Score 0, Rarely interfering with work (study and house work): Score 1, Interfering with work (study and house work) requiring lying down to rest: Score 2, Being confined to bed for 1 day, being unable to work (study and house work): Score 3.~A score for the use of analgesics is defined as follows. None: Score 0, An analgesic was used for a day during the last (or current) menstruation period: Score 1, An analgesic was used for 2 days during the last (or current) menstruation period: Score 2, An analgesic was used for 3 days during the last (or current) menstruation period: Score 3" (NCT02921763)
Timeframe: Baseline, 1 month, 2 months, 3 months, 4 months, and 5 months.

Interventionscore on a scale (Mean)
Cycle 1-0.54
Cycle 2-0.90
Cycle 3-1.02
Cycle 4-0.96
Cycle 5-1.00

[back to top]

Change Over Time in Visual Analogue Scale (VAS) for Dysmenorrhea

"A straight line with a total length of 10 cm was prepared. This straight line was defined as no pain at the left end and Worst pain imaginable at the right end.~The cases marked the degree of pain on this straight line at each time point, and the length (cm) from the left end of the line (0) was measured.~The minimum value of VAS is 0 cm (no pain) and the maximum value is 10 cm (Worst pain imaginable).~The units on a scale is cm." (NCT02921763)
Timeframe: Baseline, 1 month, 2 months, 3 months, 4 months, and 5 months.

Interventioncm (Mean)
Cycle -14.33
Cycle 13.35
Cycle 22.54
Cycle 32.37
Cycle 42.03
Cycle 52.01

[back to top]

Assessing the Difference Between the Follicular Phase of the Progestin Primed Double Stimulation Protocol and the First Round of the Conventional GnRH Antagonist Protocol Regarding the Number of M2 Oocytes Retrieved .

it is the number of M2 oocytes retrieved that were being assessed after denudation.so as to study the effect of the progestin used on the ovarian response in poor ovarian responders, we have compared the follicular phase of the dual stimulation group and first follicular wave of the flexible antagonist group (NCT04537078)
Timeframe: 1-2 hours after oocyte retrieval

Interventionnumber of oocytes (Median)
The Follicular Phase of the Double Stimulation Group2
the First Round of the Conventional GnRH Antagonist Group2

[back to top]

Assessing the Difference Between the Follicular Phase of the Progestin Primed Double Stimulation Protocol and the First Round of the Conventional GnRH Antagonist Protocol Regarding the Resultant Embryos Number.

it is the number of the resultant embryos counted at day 3 or 4 or 5 after fertilization.so as to study the effect of the progestin used on the ovarian response and the resultant embryos number in poor ovarian responders, we have compared the follicular phase of the dual stimulation group and first follicular wave of the flexible antagonist group (NCT04537078)
Timeframe: at day 3 or 4or 5 after fertilization

Interventionpercentage (Mean)
The Follicular Phase of the Double Stimulation Group1.66
the First Round of the Conventional GnRH Antagonist Group1.69

[back to top]

the Clinical Pregnancy Rate.

percentage of cases in which observation of a gestational sac with fetal heart beat by transvaginal ultrasound at 6 weeks of pregnancy (NCT04537078)
Timeframe: at the 6 th weeks of pregnancy

Interventionpercentage of participants (Number)
the Progestin Primed Double Stimulation Group7
the Flexible GnRh Antagonist Group8

[back to top]

the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Fertilization Rate.

percentage of transformation of micro injected oocytes into two pronuclei at 16 -20 hours after microinjection of the oocytes by the sperms so as to the difference between the results between the two phases, the follicular phase and the luteal phase of the progestin primed double stimulation protocol (NCT04537078)
Timeframe: 16 to 20 hours after microinjection of the oocytes with the sperms

Interventionpercentage (Median)
the Follicular Phase of the Progestin Primed Double Stimulation Group66.67
the Luteal Phase of the Progestin Primed Double Stimulation Group100

[back to top]

the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Number of M2 Oocytes Retrieved

it is the number of M2 oocytes retrieved that were being assessed after denudation so as to the difference between the results between the two phases, the follicular phase and the luteal phase of the progestin primed double stimulation protocol (NCT04537078)
Timeframe: 1-2 hours after oocyte retrieval

Interventionnumber of oocytes (Median)
the Follicular Phase of the Progestin Primed Double Stimulation Group2
the Luteal Phase of the Progestin Primed Double Stimulation Group4

[back to top]

the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Resultant Embryos Number

the resultant embryos number are counted day 3 or 4 or 5 after fertilization so as to the difference between the results between the two phases, the follicular phase and the luteal phase of the progestin primed double stimulation protocol (NCT04537078)
Timeframe: the embryos number counted day 3 or 4or 5 after fertilization

Interventionnumber of embryos (Median)
the Follicular Phase of the Progestin Primed Double Stimulation Group1
the Luteal Phase of the Progestin Primed Double Stimulation Group3

[back to top]

the Resultant Embryos Number

it is the resultant embryos number counted day 3 or 4 or 5 after fertilization (NCT04537078)
Timeframe: the embryos number counted day 3 or 4or 5 after fertilization

Interventionnumber of embryos (Median)
the Progestin Primed Double Stimulation Group4
the Flexible GnRh Antagonist Group3

[back to top]

the Number of M2 Oocytes Retrieved

it is the number of M2 oocytes retrieved that were being assessed after denudation (NCT04537078)
Timeframe: 1-2 hours after oocyte retrieval

Interventionoocytes (Median)
the Progestin Primed Double Stimulation Group6
the Flexible GnRh Antagonist Group4.5

[back to top]

the Implantation Rate

it is calculated as the number of intrauterine gestational sacs observed by transvaginal ultrasonography divided by the number of transferred embryos at the 6 th week of pregnancy and then multiplied by 100 (NCT04537078)
Timeframe: at the 6 th week of pregnancy

Interventionpercentage (Median)
the Progestin Primed Double Stimulation Group50
the Flexible GnRh Antagonist Group50

[back to top]

the Fertilization Rate

percentage transformation of micro injected oocytes into two pronuclei. it is done 16 to 20 hours after microinjection of the oocytes by the sperms (NCT04537078)
Timeframe: 16 to 20 hours after microinjection of the oocytes with the sperms

Interventionpercentage of transformation (Median)
the Progestin Primed Double Stimulation Group71.43
the Flexible GnRh Antagonist Group80.91

[back to top]

the Difference in the Ongoing Pregnancy Rate in Both Protocols.

Assessing the difference in the ongoing pregnancy rate when the pregnancy had completed ≥20 weeks of gestation (NCT04537078)
Timeframe: At the 20 th week of gestation

Interventionpercentage of participants (Number)
the Progestin Primed Double Stimulation Group6
the Flexible GnRh Antagonist Group5

[back to top]

the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Total Dosage of Gonadotropins Used in the Controlled Ovarian Hyperstimulation

Assessing the difference between the follicular phase and the luteal phase of the progestin primed double stimulation protocol regarding the total dosage of gonadotropins used in the controlled ovarian hyperstimulation so as to the difference between the two phases (NCT04537078)
Timeframe: From the first day of ovarian stimulation till the last day of ovarian stimulation in each phase ,the follicular and the luteal, of stimulation

InterventionIU (Median)
the Follicular Phase of the Progestin Primed Double Stimulation Group3000
the Luteal Phase of the Progestin Primed Double Stimulation Group3600

[back to top]

the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Total Days of Controlled Ovarian Hyperstimulation

the total number of days of the controlled ovarian hyperstimulation in both follicular and luteal phase of the progestin primed double stimulation protocol are studied so as to asses the difference between the two phases, the follicular phase and the luteal phase of the progestin primed double stimulation protocol (NCT04537078)
Timeframe: From the first day of ovarian stimulation till the last day of ovarian stimulation in each phase ,the follicular and the luteal, of stimulation

Interventionnumber of days (Median)
the Follicular Phase of the Progestin Primed Double Stimulation Group10
the Luteal Phase of the Progestin Primed Double Stimulation Group12

[back to top]

Assessing the Difference Between the Follicular Phase of the Progestin Primed Double Stimulation Protocol and the First Round of the Conventional GnRH Antagonist Protocol Regarding the Fertilization Rate.

it is percentage transformation of micro injected oocytes into two pronuclei.so as to study the effect of the progestin used on the ovarian response and its results in poor ovarian responders, we have compared the follicular phase of the dual stimulation group and first follicular wave of the flexible antagonist group (NCT04537078)
Timeframe: 16 to 20 hours after microinjection of the oocytes by the sperms

Interventionpercentage (Median)
The Follicular Phase of the Double Stimulation Group66.67
the First Round of the Conventional GnRH Antagonist Group91.67

[back to top]